iPAX‑2 Trial of TLX101 TX in First‑Line Glioblastoma Finishes Enrollment and Locks In Dosing Schedule
iPAX‑2 Trial of TLX101 in First‑Line Glioblastoma Hits Full Enrollment and Dosing Confirmation